Julia Fox-Rushby
Professor Julia Fox-Rushby has over has over 20 years experience in the economic evaluation of health interventions. Prior to joining HERG she was a Senior Lecturer at the London School of Hygiene & Tropical Medicine, Research Scientist at MEDTAP International and lecturer at City University, having begun her academic career originally at HERG. She has been a primary investigator of several international evaluations of public health interventions including modelling the cost-effectiveness of expanding the use of childhood vaccines, and the cost-effectiveness, alongside a clinical trial, of an evidence-based package of antenatal care. She has also undertaken numerous evaluations of malaria interventions within a variety of countries. Since joining HERG she has begun a systematic review and modelling of behaviour change interventions and a cost-effectiveness analysis of alternative pharmaco treatment pathways in neuropathic pain. Her research on the measurement and valuation of quality of life has been wide-ranging. She led development of the first generic health-related quality of life instrument in an African country (Kenya), was actively involved in the development and translation of the EQ-5D and has been an advisor to the WHOQOL group. Her research on the valuation of health encompasses several projects on the willingness to pay for health benefits and products as well as non-monetary approaches to utility assessment.
Professor Fox-Rushby has published widely, including in The Lancet, Social Science and Medicine, Health Economics, Quality of Life Research, and Vaccine. Her jointly edited textbook, with Professor John Cairns, ' Economic Evaluation' was released in 2005 and her previous book Disability Adjusted Life Years for Decision Making? was published in 2003 by the Office of Health Economics. She is a member of the editorial committees of the Scandinavian Journal of Public Health and Cost-Effectiveness and Resource Allocation, and on the HTA Clinical Trials Board .
Research interests: The generalisability of methods for, and results from, economic evaluations of health interventions; measuring and valuing the benefits of health care interventions; the cost-effectiveness of public health policies and practice.
|
|||
